Claritin and hypospadia
This article was originally published in The Tan Sheet
FDA review of possible link between loratadine and birth defects "unlikely" to impact its decision on Schering-Plough's NDAs to switch Claritin OTC, agency says, noting many non-Rx products carry labeling restrictions concerning use during pregnancy. In addition to internal review being conducted by Division of Pulmonary & Allergy Drug Products and Office of Drug Safety, agency is consulting with outside experts in review of Swedish data, other information. FDA analysis, which extends to data for Rx Clarinex (desloratadine), could be completed by late September. Separate review by European Agency for the Evaluation of Medicinal Products is ongoing (1"The Tan Sheet" May 6, 2002, p. 3)...
You may also be interested in...
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.
Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.